BEST
A double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events
- Stadium
- klaar
- Middel
- bexagliflozin
- Populatie
- Diabetes Mellitus
- Fase
- III
- First Patient In
- 26 september 2016
- Last Patient In
- 8 maart 2018
- Last Patient Last Visit
- 30 april 2019
National Lead
